Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeFianCe: DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab in Second-line Advanced Colorectal Cancer
2022-501465-40-00Phase 2Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial in colorectal cancer (CRC) comparing DKN-01 plus FOLFIRI/FOLFOX and bevacizumab with FOLFIRI/FOLFOX and bevacizumab (standard of care) (2 arms). Primary endpoint: Progression-free survival (PFS). Started Feb 2023; status: completed.
02
Drugs
sirexatamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-501465-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501465-40-00.